Diabetes and Social Issues: Evaluation of a Diabetes Education Module
PRIMO_Social
A Prospective Multi-center Evaluation of a Diabetes Education Module Specifically Addressing the Topic "Diabetes and Social Issues" in a Randomized Controlled Trial
1 other identifier
interventional
256
1 country
4
Brief Summary
This study is a multi-center, randomized prospective trial with a 6-month follow up. A newly developed treatment and education module will be tested compared to a waiting-list control group. The module covers the topic "diabetes and social issues". Primary outcome variable is diabetes-specific empowerment regarding diabetes and social issues. Secondary outcome variables are: diabetes-related distress, health-related quality of life, depressive symptoms, self-care behavior, and glycemic control.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for not_applicable diabetes-mellitus
Started Feb 2014
Longer than P75 for not_applicable diabetes-mellitus
4 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
February 1, 2014
CompletedFirst Submitted
Initial submission to the registry
February 28, 2014
CompletedFirst Posted
Study publicly available on registry
March 3, 2014
CompletedPrimary Completion
Last participant's last visit for primary outcome
January 1, 2019
CompletedStudy Completion
Last participant's last visit for all outcomes
July 1, 2019
CompletedAugust 9, 2019
August 1, 2019
4.9 years
February 28, 2014
August 7, 2019
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Change from baseline in diabetes-specific empowerment on the adapted Diabetes Empowerment Scale at the 2-week and 6-month follow-up
The Diabetes Empowerment Scale was specifically adjusted to cover the topic "social issues". Psychometric criteria for these adjusted scale were evaluated in an independent study
Baseline, 2-week follow-up , 6-month follow-up
Secondary Outcomes (7)
Change from baseline in problem-specific distress on the adapted Problem Areas in Diabetes (PAID) Scale at the 2-week and 6-month follow-up
baseline, 2-week follow-up, 6-month follow-up
Change from baseline in glycemic control (HbA1c) at the 2-week and 6-month follow-up
baseline, 2-week follow-up, 6-month follow-up
Change from baseline in health-related quality of life on the EQ-5D at the 2-week and 6-month follow-up
baseline, 2-week follow-up, 6-month follow-up
Change from baseline in quality of life on the WHO-5 at the 2-week and 6-month follow-up
baseline, 2-week follow-up, 6-month follow-up
Change from baseline in self-efficacy on the General Self-Efficacy Scale (GSE) the 2-week and 6-month follow-up
baseline, 2-week follow-up, 6-month follow-up
- +2 more secondary outcomes
Study Arms (2)
Education - Diabetes and Social Issues
EXPERIMENTALPatients randomized to this arm, will participate immediately in the education module "Diabetes and Social Issues"
Waiting-list control group
NO INTERVENTIONPatients in the control group will get the education with the education module after completion of the 6-month follow-up
Interventions
Based on the treatment and education programme PRIMAS a problem-specific education module regarding "Diabetes and Social Issues" was created. The module covers specific and detailed aspects of the topic "social issues" such as driver licence, hypoglycemia when driving, and the pass for severly handicapped persons. With this module, a more comprehensive education of patients with specific interest is possible.
Eligibility Criteria
You may qualify if:
- Intensive insulin treatment
- specific interest in "Diabetes and Social Issues"
- wish to participate in group education
- informed consent
- fluent in reading and speaking German language
You may not qualify if:
- diabetes duration \< 4 week
- severe organic disease (e.g. terminal renal disease, cancer with poor prognosis)
- current treatment of a mental disease
- cognitive impairment
- dementia
- pregnancy
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (4)
Research Institute of the Diabetes Academy Mergentheim (FIDAM)
Bad Mergentheim, 97980, Germany
Zentrum für Diabetologie Bergedorf
Hamburg, 21029, Germany
Diabeteszentrum Ludwigsburg
Ludwigsburg, 71634, Germany
Diabetologische Schwerpunktpraxis Neuss
Neuss, 41462, Germany
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Norbert Hermanns, PhD
Forschungsinstitut der Diabetes Akademie Mergentheim
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- NONE
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Head of the Research Institut Diabetes Academy Mergentheim
Study Record Dates
First Submitted
February 28, 2014
First Posted
March 3, 2014
Study Start
February 1, 2014
Primary Completion
January 1, 2019
Study Completion
July 1, 2019
Last Updated
August 9, 2019
Record last verified: 2019-08